{"disease":{"id":"sporadic-inclusion-body-myositis-sibm","name":"sporadic inclusion body myositis sibm"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06479863","title":"Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Austin Neuromuscular Center","has_results":false},{"nct_id":"NCT02250443","title":"Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}